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Previewsassays are used to monitor autophagic
activity.
Importantly, the study by Anderson
et al. (2015) demonstrates that, when
tested in mouse xenograft tumor models,
orally applied CB-5083 is well tolerated
and results in a dose-dependent induc-
tion of ER stress and apoptosis in tumor
tissues. Accordingly, the tumor volume
is significantly reduced in several xeno-
graft-based solid tumor mouse models,
whereas, in the same assay, proteasome
inhibitors are barely active. Lastly, the au-
thors close by showing that p97 expres-
sion levels and the Ras-MAPK pathway
activity correlate with the sensitivity to
CB-5083.
Overall, the new p97 inhibitor reported
here will surely serve as another invalu-
able tool to advance our understandings
on the diverse biological mechanisms
regulated by p97. Most significantly, the
demonstration that drugs disrupting the
cellular proteostasis network at another
level can effectively kill cancer cells
derived from solid tumors in mouse
models is a strong testimony to the pro-552 Cancer Cell 28, November 9, 2015 ª201teostasis addition theory, and the findings
reported here will potentially open a new
path to circumvent obstacles in treatment
of solid tumors. In this regard, the study
will certainly prompt tremendous interest
in developing additional p97 inhibitors as
well as inhibitors targeting other proteo-
stasis regulators. Structural validation of
the inhibitor-p97 interactions will certainly
be launched in order to come up with
rational designs to improve p97 inhibitors,
which may overcome the inevitable rise
of resistance to the current inhibitor.
Meanwhile, given the great pharmacolog-
ical property, low toxicity to normal cells,
easy administration route, strong potency,
and high specificity, CB-5083 seems to
have a good chance to endure through
the long and costly clinical testing and
bring significant benefit to patients bearing
proteostasis-addicted tumors.
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Real-time monitoring of changes in cells or cell products released from malignant lesions into the blood has
opened new diagnostic avenues (‘‘liquid biopsy’’). In this issue of Cancer Cell, Best and colleagues describe
that tumor-associated blood platelets provide specific information on the location and molecular composi-
tion of the primary tumor.The peripheral blood of a cancer patient
is a pool of cells and/or cell products
derived from the primary tumor and
different metastatic sites, including cir-
culating tumor cells (CTCs) and stromal
cells of the tumor microenvironment (e.g.,
macrophages) as well as tumor-derived
DNA, RNA, and proteins. The analysis of
these blood components can, therefore,provide a comprehensive real-time picture
of the tumor-associated changes in an in-
dividual cancer patient (Figure 1). This in-
formation can be used for screening and
early detection of cancer, estimation of
the risk for metastatic relapse or progres-
sion (prognostic information), stratification
and real-time monitoring of treatment
response, identification of therapeutic tar-gets and resistance mechanisms (biolog-
ical therapies), and a better understanding
of the biology of metastatic development.
Incontrast to tissuebiopsies,bloodsam-
ples can be obtained easily and repeatedly
from cancer patients. In the last decade,
many reports have focused on CTCs and
circulating nucleic acids (in particular, tu-
mor-derived DNA fragments and various
DNA, RNA, proteins
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Figure 1. Sources of Liquid Biopsy
Blood can be separated into different fractions in order to enrich for tumor-associated biomarkers. From
the mononuclear cell fraction, circulating tumor cells (CTCs) may provide genomic, transcriptomic, and
proteomic information on the tumor. From plasma or serum, cell-free nucleotides and exosomes can be
further used to interrogate cancer-secreted bioparticles. Tumor educated platelets (TEPs) carry additional
information on the location of the tumor in their mRNA.
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PreviewsmiRNA species) (Alix-Panabie`res and Pan-
tel, 2014). More recently, the molecular
analysis of tumor-derived microvesicles,
in particular, exosomes (Melo et al., 2015),
has broadened the spectrum of liquid bi-
opsy applications. Regarding the clinical
relevance, molecular analysis of CTCs
and circulating tumor DNA (ctDNA) pro-
vides important information on therapeutic
targets anddrug resistancemechanisms in
carcinoma patients. Although the ctDNA
field is restricted to DNA analyses, investi-
gation of CTCs allows comprehensive
studies at the DNA, RNA, and protein level
as well as functional studies including the
establishment of cell lines and xenografts
(Cayrefourcq et al., 2015).
Besides tumor cells and their products,
normal cells present in the tumormicroen-
vironment are also released into the blood
stream, and these cells can harbor impor-
tant information. In this issue of Cancer
Cell, Best et al. (2015) describe an impor-
tant potential role of tumor-educated
blood platelets (TEPs). The biology behindthis new diagnostic role of TEPs is the
well-known interaction between blood
platelets and tumor cells that is known to
affect tumor growth and dissemination
(Kuznetsov et al., 2012). This interaction
affects not only the expression of relevant
genes in tumor cells, but also alters the
RNA profile of blood platelets (Best et al.,
2015). In total, Best et al. (2015) performed
mRNA sequencing of TEPs from 283
platelet samples and distinguished 228
patients with localized and metastasized
tumors from 55 healthy individuals with
96% accuracy. Across six different tumor
types (non-small cell lung carcinoma,
colorectal cancer, glioblastoma, pancre-
atic cancer, hepatobiliary cancer, and
breast cancer), the location of the primary
tumor was correctly identified with 71%
accuracy. Moreover, MET or ERBB2-pos-
itive and mutant KRAS, EGFR, or PIK3CA
tumors were accurately distinguished us-
ing surrogate TEP mRNA profiles.
Interestingly, the tumor-specific educa-
tional programs in TEPs were predomi-Cancer Cell 28,nantly influenced by tumor type and, to a
lesser extent, by tumor progression and
metastases (i.e., no significant differences
between non-metastasized and metasta-
sized tumorsweredetected). This is some-
what surprising, because experimental
work has shown an influence of blood
platelets on tumor cell dissemination (La-
belle et al., 2011) andmetastatic outgrowth
(Kuznetsov et al., 2012). A possible expla-
nationmight be the low number of patients
analyzed for each tumor type, which may
not allow a statistically meaningful stratifi-
cation in localized and metastatic tumors.
Moreover, the set of tumors analyzed was
very heterogeneous with regard to the
metastatic capacities, e.g., glioblastomas
can release tumor cells into the blood cir-
culation but almost never produce overt
metastases, while pancreatic and lung
cancer are frequently metastasized at pri-
mary diagnosis. Thus, larger andmore ho-
mogeneous datasets are required to
address the important question of whether
TEPs sequencing can also reveal informa-
tionon the riskofmetastatic relapse,which
is the dominant cause of cancer-related
deaths in most malignancies.
Although the findings ofBest et al. (2015)
are very exciting, the requirements for
introducing a new cancer screening test
into practice are very high. The presented
case-control study is a good start, but
much larger cohorts of individuals at risk
need to be analyzed and followed up pro-
spectively over many years. For example,
cancer screening studies on prostate-spe-
cific antigen (PSA) in prostate cancer or
mammography in breast cancer com-
prised ten thousands of individuals at risk
and follow-up time of 10 or more years.
Focusing on study populations at very
high risk (e.g., people with a predisposition
for cancer)might reduce this effort to some
extent.Moreover,many aging people have
benign tumors (e.g., skin tumors) or leu-
kocytes carrying cancer-associatedmuta-
tions (Genovese et al., 2014), and
this may cause false-positive findings.
Finally, despite all diagnostic efforts, early
detectionofcancermightnotalways trans-
late into reduced mortality because tumor
cell disseminationcanoccurveryearlydur-
ing tumorigenesis and surgical removal of
the primary lesion is no guarantee for cure.
In contrast, the second key finding of
Best et al. (2015) that TEPs mRNA profiles
could distinguish mutant KRAS, EGFR, or
PIK3CA tumors could be readily validatedNovember 9, 2015 ª2015 Elsevier Inc. 553
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Previewsin future prospective clinical trials in which
cancer patientswill receive targeted thera-
pies based on these profiles. This is a very
important application inmodern oncology.
Besides, novel chemotherapy drugs (e.g.,
antibodies or small inhibitors) that target
specific receptors or molecular pathways
on cancer cells have been developed
over the past ten years (Wan et al., 2013).
Although these drugs are administered to
target metastatic cells, current stratifica-
tion of therapy is based largely on the anal-
ysis of the resected primary tumor. How-
ever, metastases occur in many patients
years after primary tumor diagnosis, and
they can harbor unique genomic alter-
ations different from the bulk of the original
primary tumor cells (Kang and Pantel,
2013). Thus, thedirect analysisofmetasta-
tic cells will reveal important information
for a systemic cancer therapy targeting
metastatic disease. However, a biopsy of
overt metastases is an invasive procedure
limited to certain locations and not easily
acceptable in the clinic. Moreover, recent
work has shown that different metastatic
sites harbor different genomic aberrations,
and biopsies of one or two accessible me-
tastases may not be representative. Thus,
the assessment of the TEP mRNA profile
might provide real-time information on
the actual status of metastatic lesions. In
this regard, future comparative studies
will show whether the TEP approach is su-554 Cancer Cell 28, November 9, 2015 ª201perior or complementary to othermeansof
liquidbiopsy (e.g., ctDNAorCTCanalyses)
in stratifying individual patients to the
appropriate therapy.
Before these clinical trials can be con-
ducted, the robustness of the assay and
factors confounding the blood platelet
mRNA profile need to be investigated.
The authors recommend isolation of the
platelet fraction within 48 hr after blood
withdrawal; however, research on many
cell types has indicated that mRNA pro-
files will change during this time period.
In addition, systemic factors such as
chronic or transient inflammatory dis-
eases or cardiovascular events and other
non-cancerous diseases may also influ-
ence the platelet mRNA profile.
Taken together, the ability of TEPs to
pinpoint the location of the primary tumor
might advance the use of liquid biopsies
for cancer diagnostics. Further validation
is warranted to determine the clinical utility
of TEP profiles for blood-based liquid bi-
opsy. The validationof liquidbiopsyassays
is an important task of the new European
consortium CANCER-ID that comprises
more than 30 institutions from academia
and industry (http://www.cancer-id.eu).ACKNOWLEDGMENTS
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Metastasis to distant organs depends on pathological crosstalk between tumor cells and various tissue-spe-
cific stromal components. Zhang and colleagues recently demonstrated that astrocyte-derived exosomal
miR-19a reversibly downregulated PTEN expression in cancer cells, thereby increasing their CCL2 secretion
and recruitment of myeloid cell to promote brain metastasis.Stephen Paget’s visionary ‘‘seed and soil’’
hypothesis underscored the importance
ofmutual compatibility between tumor cellsand host organs in the formation of
metastatic lesions. Such compatibility may
stem from the intrinsic characteristics ofcancer cells and the host microenvi-
ronments, but could also be developed
though their co-evolution during adaptive
